Rocephin — HCPCS J0696 · Ceftriaxone

About ceftriaxone (Rocephin) FDA label verified Jul 2026

Ceftriaxone is a third-generation cephalosporin antibiotic with a long half-life that supports once-daily dosing and broad gram-negative and gram-positive coverage across a wide range of infections. That combination — once-daily, broad-spectrum, no renal dose adjustment needed — is exactly why the Infectious Diseases Society of America (IDSA) treats ceftriaxone as a first-line, gold-standard agent for outpatient parenteral antibiotic therapy (OPAT): a single daily infusion or IM injection can bridge a hospital discharge to a completed course of therapy with minimal nursing burden compared to agents dosed multiple times a day.

The Rocephin name is now largely historical for billing purposes: Roche’s branded product is no longer commercially marketed in the United States and does not appear in the current CMS ASP pricing file. Every currently priced NDC is generic — Hikma/West-Ward, Hospira/Pfizer, B. Braun and Baxter (both marketing premixed ceftriaxone in D5W), Sandoz, and other manufacturers all bill the identical J0696 at 250 mg per unit. This matters for billers in two ways: first, there is no manufacturer-specific code split to track (unlike daptomycin’s J0877/J0872–J0874 trap) — every ceftriaxone NDC bills J0696; second, there is no manufacturer copay program to route patients to, because the drug is inexpensive enough on ASP that the cost conversation barely registers compared to most specialty infusibles on this site.

Three features drive ceftriaxone claim accuracy. First, adult dosing is a flat dose (not weight-based) — 1–2 g once daily for most indications — which, combined with the 250 mg billable unit, means the standard claim is zero-waste. Second, it ships in four single-dose vial sizes (250 mg, 500 mg, 1 g, 2 g) plus a separate 10 g pharmacy bulk package that is not intended for direct patient infusion — a real billing trap if the pharmacy system keys units off the bulk NDC instead of the single-dose vial actually drawn from. Third, ceftriaxone carries a hard, sometimes fatal, contraindication with calcium-containing IV solutions in neonates — a clinical-safety issue with direct implications for line management and documentation in home infusion and NICU-adjacent settings.

One reassuring fact belongs at the top of any ceftriaxone billing reference: as of this review, ceftriaxone does not appear on any of the eight Medicare Administrative Contractors’ Self-Administered Drug (SAD) exclusion lists. Billers new to OPAT antibiotics sometimes assume any outpatient-administered antibiotic carries SAD risk the way certain self-injectable specialty drugs do — ceftriaxone doesn’t, because it requires IV or IM administration by a healthcare professional, not self-injection.

Brand vs generic, and the vial-size decision that matters CMS HCPCS aligned Jul 2026

Ceftriaxone has no manufacturer-specific code split -- every generic NDC bills J0696 at 250 mg per unit. The decision that actually matters is which of the five package sizes was used.

Unlike daptomycin, where CMS maintains separate manufacturer-specific J-codes for different suppliers, ceftriaxone has a single, simple billing story: every generic manufacturer’s NDC bills J0696 at 250 mg per unit, and brand Rocephin (Roche) — no longer commercially marketed in the US — would bill the same code if it were still available. The complexity that does exist is on the package side, not the code side: ceftriaxone is sold in five distinct package types, and only four of them are meant to leave the pharmacy as a single patient’s dose.

Dose, units & the zero-waste vial math FDA label verified Jul 2026

J0696 is billed at 1 unit = 250 mg. Because adult dosing is flat (not weight-based) and every standard dose is an exact multiple of 250 mg, the typical ceftriaxone claim has zero waste.

FDA-labeled adult dosing (flat dose, not weight-based)

Worked example — standard 1 g and 2 g adult doses (zero waste)

Compatibility & the calcium-containing solution contraindication

Ceftriaxone and calcium-containing IV solutions — lactated Ringer’s, Ringer’s solution, or any calcium-containing product including TPN with calcium — can form a precipitate. This has caused fatal outcomes in neonates when the precipitate formed in the lungs and kidneys. Ceftriaxone is contraindicated in premature neonates through 41 weeks postmenstrual age, in hyperbilirubinemic neonates, and in any neonate requiring (or expected to require) calcium-containing IV products. In patients older than 28 days, ceftriaxone and calcium-containing solutions may be administered sequentially if the line is thoroughly flushed with a compatible fluid between infusions, but should never be given simultaneously through the same line or Y-site. This is a clinical-safety and OPAT/home-infusion line-management issue, not a coding nuance — it belongs in the care plan for any TPN-dependent home patient receiving ceftriaxone.

NDC reference NDCs verified vs the CMS NDC-HCPCS crosswalk, Jul 2026

Multiple generic manufacturers, all four single-dose vial sizes plus the 10 g bulk package represented. Every NDC below maps to J0696 at 250 mg per unit.

Administration codes CPT verified Jul 2026

Ceftriaxone is a therapeutic (non-chemotherapy) drug that can be given as an IV infusion or an IM injection -- match the CPT to the route actually used.

Full code guidance: 96365/96366 · all admin CPT references.

Home infusion & ED/urgent-care volume

When ceftriaxone is delivered through a home-infusion or OPAT program for a multi-day course (bone/joint infection, endocarditis, extended step-down therapy), the drug J-code stays on the home-infusion pharmacy’s claim, while the per-diem service or per-visit professional code is billed separately. Commercial/Medicaid plans use the home-infusion antibiotic S-code family (S9494 umbrella total-per-diem; S9500 for every-24-hour dosing, matching ceftriaxone’s typical cadence). Medicare’s Home Infusion Therapy benefit uses G-codes G0068–G0070 by drug category. See the IV antibiotics reference for the full S-code/G-code table. Distinct from the OPAT use case, ceftriaxone is also an extremely high-volume single-dose drug in the emergency department and urgent care (gonorrhea, surgical prophylaxis, empiric first dose before discharge) — those claims are simple office/ED visits with no separate service-code layer.

Modifiers CMS verified Jul 2026

JZ / JW — single-dose vial rule, and why JZ dominates here

Per CMS’s July 2023 single-dose-container policy (CR 12056), every J0696 claim built from a single-dose vial needs exactly one of JZ (no discard) or JW (discard). Because adult dosing is a flat dose and the 250 mg unit divides evenly into every standard adult dose (500 mg, 1 g, 2 g), JZ is the dominant case — the opposite pattern from a weight-based drug like daptomycin.

Modifier 25 — same-day E/M

Append modifier 25 to the office/ED E/M (99202–99215, or the ED E/M family) when a significant, separately identifiable evaluation and management service is performed the same day as the injection or infusion — common for the single-dose ED visit where the diagnosis is established and treated in the same encounter, or at OPAT initiation.

340B modifiers (JG, TB) & KX

For 340B-acquired ceftriaxone at eligible covered entities, follow your MAC’s current 340B modifier policy (JG or TB as directed). KX is rarely needed for ceftriaxone given how broadly it is covered, but check payer policy for any above-label pediatric dosing or extended OPAT course.

ICD-10-CM by indication FY2026 · verified Jul 2026

Ceftriaxone's FDA label covers a wide range of indications -- pair the diagnosis with the specific infection actually being treated.

Site of care & OPAT Verified Jul 2026

Ceftriaxone’s once-daily dosing, no-renal-adjustment profile, and broad-spectrum coverage make it the IDSA-recognized gold-standard first-line agent for outpatient parenteral antibiotic therapy across a wide range of step-down indications — bone/joint infection, endocarditis, complicated UTI, and more. It is also, separately, one of the highest-volume single-dose drugs in the emergency department and urgent-care setting (gonorrhea, surgical prophylaxis, and empiric coverage before discharge).

Claim form field mapping CMS verified Jul 2026

Office/ED/HOPD ceftriaxone is a CMS-1500 (837P) or UB-04 (837I) claim. OPAT/home infusion for extended courses splits into a drug claim and a separate service claim.

Payer policy snapshot Reviewed Jul 2026 · verify current policy

Ceftriaxone is broadly covered for its wide range of FDA-labeled indications; because it's generic and inexpensive, payers apply little of the utilization management seen on newer or single-dose specialty antibiotics.

Why ceftriaxone sees minimal utilization management

Because ceftriaxone is generic, inexpensive, and has been a first-line agent for decades, payers generally don’t apply the step-therapy or prior-authorization edits used for newer, high-cost agents (the single-dose lipoglycopeptides, ceftazidime-avibactam, meropenem-vaborbactam) or even for other IV antibiotics with a narrower coverage profile. The scrutiny that does exist concentrates on extended OPAT course length (courses beyond a couple of weeks may need renewal documentation) and on confirming the correct site-of-care bundling rules (SNF consolidated billing, surgical prophylaxis bundling).

Confirmed absent from every MAC's SAD list

As of this review, a check of all eight Medicare Administrative Contractors’ published Self-Administered Drug exclusion articles found no listing for ceftriaxone. This is a meaningful reassurance for billers new to OPAT antibiotics, who sometimes assume any outpatient-administered drug carries SAD risk — ceftriaxone requires professional IV or IM administration, not self-injection, so it does not fit the SAD exclusion criteria. No drug-specific Local Coverage Determination (LCD) or coverage article was identified either. Always confirm current MAC policy before assuming this is permanent, since SAD lists and coverage articles can be added or changed.

Medicare reimbursement — J0696 reimbursement (2026) CMS ASP verified Q2 2026

J0696 is an ASP-priced Part B drug. At the current ASP, ceftriaxone is one of the least expensive drugs on this site -- the administration fee and, for OPAT courses, the home-infusion service charge dominate the patient's real cost.

Coverage

There is no ceftriaxone-specific NCD; coverage runs through the standard Medicare Part B drug framework for FDA-approved indications. No SAD-list exclusion (confirmed absent from all eight MACs as of this review) and no drug-specific LCD/article were identified.

Code history

• J0696 — permanent HCPCS, "Ceftriaxone sodium injection," 250 mg per unit. Applies to every currently ASP-priced NDC; brand Rocephin (Roche) is no longer commercially marketed and does not appear in the current ASP file.

Patient assistance Verified Jul 2026

Like daptomycin, ceftriaxone is a drug where the honest answer is: there isn't a copay-assistance program to look for, and there usually doesn't need to be one. Because brand Rocephin is no longer commercially marketed and every currently ASP-priced NDC is generic, the drug cost itself is pennies per unit — the worked examples above show a full 2 g dose costing about $3.65 in allowed drug charges, with a ~20% Medicare coinsurance around $0.73.

• No manufacturer copay card. Roche does not maintain a patient-assistance program for Rocephin because the branded product is no longer commercially marketed in the US. There is no active manufacturer assistance program for generic ceftriaxone.
• Generic cost-sharing programs — standard hospital/practice financial-assistance policies and, where applicable, 340B pricing for eligible covered entities are the relevant cost levers, not a branded copay card.
• Foundation copay funds for infectious-disease indications are uncommon and not the primary relief mechanism here, given how low the underlying drug cost already is.
• Where cost actually shows up: the administration fee, the ED/facility visit charge, and — for OPAT courses — the home-infusion service charges (nursing, supplies, PICC line placement, per-diem S-codes) dwarf the drug cost itself. That's where a patient's true out-of-pocket exposure and any financial-assistance conversation should focus.

Common denials & how to fix them Reviewed Jul 2026

Frequently asked questions

What is the HCPCS J-code for Rocephin (ceftriaxone)?

Ceftriaxone — the brand Rocephin is off the US market, so every currently ASP-priced NDC is generic — is billed under HCPCS J0696, defined at 250 mg per unit. One billed unit = 250 mg, so a standard 1 g dose is J0696 × 4 and a 2 g dose is J0696 × 8. There is no manufacturer-specific code split the way daptomycin has: every generic ceftriaxone manufacturer’s NDC bills the same J0696.

How do I bill Rocephin/ceftriaxone vial waste with JW and JZ?

Ceftriaxone ships in 250 mg, 500 mg, 1 g, and 2 g single-dose vials, and because the 250 mg unit divides evenly into essentially every FDA-labeled adult dose (500 mg, 1 g, 2 g), the standard adult claim has zero waste — bill the full administered-units line with modifier JZ. JW only appears in the rare case of a pediatric weight-based dose that, once rounded to a practical mg amount, doesn’t land on an exact 250 mg multiple against the vial drawn — in that case the administered line carries no modifier and a separate JW line reports the discarded mg. Never bill JZ and JW together for the same drug on the same date of service.

Is ceftriaxone (Rocephin) on Medicare's Self-Administered Drug (SAD) exclusion list?

No. As of this review, ceftriaxone does not appear on any of the eight Medicare Administrative Contractors’ Self-Administered Drug exclusion lists. Billers sometimes assume outpatient IV/IM antibiotics carry SAD risk the way some self-injectable specialty drugs do — ceftriaxone doesn’t, because it is not a self-administered product; it requires IV or IM administration by a healthcare professional. This does not eliminate the need to check your specific MAC's current list, since SAD lists can change.

Can ceftriaxone be given through the same IV line as calcium-containing fluids?

Not in neonates, and with caution in older patients. Ceftriaxone and calcium-containing IV solutions (lactated Ringer’s, Ringer’s solution, or any calcium-containing product, including calcium-containing total parenteral nutrition) can form a precipitate. This has caused fatal outcomes in neonates when the precipitate formed in the lungs and kidneys. Ceftriaxone is contraindicated in neonates who require, or are expected to require, calcium-containing IV products, and in patients of any age it should not be mixed or co-administered simultaneously through the same line; separate lines, or sequential administration with a thorough line flush, is the standard mitigation in patients over 28 days old.

What is the ceftriaxone dose for common adult infections?

Adult dosing is a flat dose, not weight-based: 1–2 g IV or IM once daily for most FDA-labeled indications (pneumonia, skin infections, complicated UTI, intra-abdominal infection, bone/joint infection, surgical prophylaxis at 1 g), up to a maximum of 4 g/day. Adult bacterial meningitis is commonly dosed at 2 g every 12 hours per IDSA guidance — that q12h pattern reaches the label's 4 g/day maximum but is itself a guideline regimen, not label text. Uncomplicated gonorrhea is a single 500 mg IM dose per current CDC guidance (1 g if the patient weighs 150 kg or more). Pediatric dosing is weight-based (50–75 mg/kg/day; meningitis per the label: initial 100 mg/kg, then 100 mg/kg/day, max 4 g/day) and is where JW discard is most likely to appear.

Does Rocephin (ceftriaxone) have a manufacturer copay card?

No. Ceftriaxone is fully generic — Roche’s branded Rocephin is no longer commercially marketed in the US and does not appear in the current CMS ASP file. There is no active manufacturer patient-assistance or copay program for ceftriaxone. The practical cost story is that the drug itself is inexpensive (a few cents per 250 mg unit at ASP), so even Medicare’s 20% coinsurance on a full 2 g dose is well under a dollar — the administration fee and, for OPAT courses, the home-infusion service charges are what actually drive a patient’s out-of-pocket cost.

What is the difference between the single-dose vials and the pharmacy bulk package?

The 250 mg, 500 mg, 1 g, and 2 g vials (and the premixed 1 g/2 g bags in D5W) are single-dose containers meant to be administered directly to one patient. The separate 10 g pharmacy bulk package is intended only for a pharmacy to compound multiple individual patient doses under USP compounding rules — it is not itself a billable single-patient dose. Billing units as if the bulk package were a single-dose vial produces grossly incorrect claims; always confirm the NDC of the specific container the administered dose was drawn from.

Source documents

1. DailyMed — Ceftriaxone (Rocephin) prescribing information
   Current FDA label; indications, flat adult dosing, pediatric mg/kg dosing, calcium-solution contraindication, monitoring
2. CMS HCPCS Level II — J0696
   "Ceftriaxone sodium injection," 250 mg per unit; applies to every currently priced generic manufacturer's NDC
3. CMS — Medicare Part B Drug ASP Pricing File
   Quarterly ASP+6% pricing; J0696 = $0.430/250 mg unit (Q2 2026), live-bound on this page
4. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
   Single-dose-container discard reporting; applies to ceftriaxone's 250 mg/500 mg/1 g/2 g single-dose vials
5. FDA National Drug Code Directory — ceftriaxone NDCs
   Verify the 11-digit NDC for the exact single-dose vial or bulk package used
6. AMA CPT — therapeutic IV infusion and IM/SC injection codes (96365, 96366, 96372)
   Administration coding for infusion vs IM injection; not chemotherapy administration
7. CDC Sexually Transmitted Infections Treatment Guidelines (2021) — gonorrhea
   Current single-dose IM ceftriaxone regimen for uncomplicated gonorrhea, including the ≥150 kg dose adjustment
8. Infectious Diseases Society of America (IDSA) — OPAT clinical practice guideline (2018)
   Gold-standard-agent framing; OPAT documentation elements (ID consult, access plan, monitoring, step-down)
9. CMS — ICD-10-CM (FY2026)
   Representative codes across ceftriaxone's broad FDA-labeled indication list
10. CMS Medicare Coverage Database — Self-Administered Drug Exclusion Articles (all 8 MACs)
    Checked all eight MAC SAD exclusion lists; ceftriaxone/J0696 confirmed absent from every one as of this review. Also searched for a drug-specific NCD/LCD/coverage article; none found.

About this page

We maintain this page as a living reference for billers, coders, and revenue-cycle staff working with ceftriaxone claims in emergency medicine, infectious disease, and OPAT/home-infusion programs. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes. The J0696 ASP figure is live-bound to the CareCost CMS ASP layer, so the per-unit price reflects the current quarter automatically.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• Jul 14, 2026 — Initial publication. Ceftriaxone (Rocephin) billing reference: J0696 at 250 mg/unit with live ASP binding; brand-discontinued/generic-only clarification with no manufacturer-code split; 250 mg/500 mg/1 g/2 g single-dose vial zero-waste JZ math contrasted with the 10 g pharmacy bulk package billing trap; flat (non-weight-based) adult dosing by indication with worked examples; confirmed absence from all 8 MAC Self-Administered Drug exclusion lists; therapeutic IV infusion/IM injection admin codes; fatal neonatal calcium-solution contraindication; OPAT/ED site-of-care economics; confirmed no manufacturer copay program.

Methodology

Every claim on this page is sourced inline. Dosing, indications, the calcium-solution contraindication, and monitoring requirements are taken from the current FDA prescribing information; the ASP figure is read live from the CMS Part B ASP file; administration codes are from AMA CPT; gonorrhea dosing follows current CDC guidance; the SAD-list status was checked against all eight MAC exclusion lists directly. We do not paraphrase from billing-software vendor blogs, and we flag anything not yet SME-verified rather than assert it.